Rapid Micro Biosystems (RPID) Expected to Release Quarterly Earnings on Friday

Rapid Micro Biosystems (NASDAQ:RPID) will likely be announcing its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect the company to post earnings of ($0.26) per share and revenue of $7.8750 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 7, 2026 at 8:30 AM ET.

Rapid Micro Biosystems (NASDAQ:RPID) last issued its earnings results on Wednesday, May 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.06). Rapid Micro Biosystems had a negative net margin of 145.81% and a negative return on equity of 131.52%. The company had revenue of $8.00 million during the quarter, compared to analysts’ expectations of $7.60 million. On average, analysts expect Rapid Micro Biosystems to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rapid Micro Biosystems Stock Up 2.4%

Shares of RPID opened at $2.11 on Thursday. Rapid Micro Biosystems has a 52-week low of $1.66 and a 52-week high of $4.94. The company has a quick ratio of 1.66, a current ratio of 2.57 and a debt-to-equity ratio of 0.93. The stock has a fifty day simple moving average of $1.90 and a two-hundred day simple moving average of $2.69. The company has a market capitalization of $97.42 million, a PE ratio of -1.88 and a beta of 1.44.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on RPID shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapid Micro Biosystems in a report on Friday, July 17th. KeyCorp reduced their target price on shares of Rapid Micro Biosystems from $8.00 to $5.00 and set an “overweight” rating on the stock in a research note on Friday, May 29th. Wall Street Zen upgraded shares of Rapid Micro Biosystems from a “strong sell” rating to a “sell” rating in a report on Sunday, May 31st. Finally, Lake Street Capital dropped their price target on shares of Rapid Micro Biosystems from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, May 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Rapid Micro Biosystems presently has a consensus rating of “Hold” and a consensus target price of $6.00.

Institutional Trading of Rapid Micro Biosystems

Several institutional investors and hedge funds have recently bought and sold shares of RPID. Vanguard Group Inc. lifted its position in Rapid Micro Biosystems by 6.7% in the third quarter. Vanguard Group Inc. now owns 965,018 shares of the company’s stock valued at $3,223,000 after buying an additional 60,655 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Rapid Micro Biosystems by 6.3% during the fourth quarter. Geode Capital Management LLC now owns 217,568 shares of the company’s stock valued at $631,000 after acquiring an additional 12,881 shares during the last quarter. 683 Capital Management LLC purchased a new stake in shares of Rapid Micro Biosystems in the 4th quarter valued at approximately $350,000. Millennium Management LLC purchased a new stake in shares of Rapid Micro Biosystems in the 4th quarter valued at approximately $338,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Rapid Micro Biosystems by 4.9% in the 4th quarter. Renaissance Technologies LLC now owns 115,627 shares of the company’s stock worth $335,000 after acquiring an additional 5,440 shares during the last quarter. 52.60% of the stock is currently owned by hedge funds and other institutional investors.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.